Photo from wikipedia
www.thelancet.com Vol 389 March 25, 2017 1193 in ANTARCTIC was de-intensification to clopidogrel in an attempt to reduce bleeding. In the GENERATIONS and TRILOGY ACS trials, the bleeding rates were… Click to show full abstract
www.thelancet.com Vol 389 March 25, 2017 1193 in ANTARCTIC was de-intensification to clopidogrel in an attempt to reduce bleeding. In the GENERATIONS and TRILOGY ACS trials, the bleeding rates were the same between the prasugrel 5 mg and clopidogrel 75 mg groups. Therefore, the ANTARCTIC results were unsurprisingly unsupportive of personalisation. Given these important limitations, the study is insufficient to refute the utility of personal is ing antiplatelet therapy, and therefore the authors are overreaching with their generalised statements in the interpretation about how the study results should influence guideline recommendations.
Journal Title: The Lancet
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!